Endovascular therapy of direct dural carotid cavernous fistulas - A therapy assessment study including long-term follow-up patient interviews.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 30 04 2019
accepted: 22 09 2019
entrez: 18 10 2019
pubmed: 18 10 2019
medline: 17 3 2020
Statut: epublish

Résumé

Endovascular embolization nowadays is a well-established treatment option for direct carotid cavernous fistulas (dCCF, Barrow Type A). There are many publications on the complication and success rates of this method. However, little is known on the patients´ opinion on the treatment result after several years. We report on this issue also including the "pioneer patients" treated almost two decades ago. We retrospectively reviewed the records of all patient (n = 25) with a more than 24 months follow-up interval after endovascular treatment of a dCCF at our institution from 01/1999 to 08/2018. We determined primary therapy success, complication rate, state of the fistula in the last imaging follow-up and quoted the patient's subjective perception of the long-term treatment success using a standardized interview form. Occlusion rate in the last imaging follow up was 96% (24/25) with a complication rate of 8% (2/25). The response rate on our interview request was 96% (24/25) with a rate of considered feedback of 84% (21/25 patients). Duration of our observation interval for the patient reported outcome was 143 months / 11 years (median, range: 35-226 m / 2-18 y). Most of them (21/25, 84%) felt they benefited from the treatment. Endovascular supply of dCCF is a highly effective treatment method leading to a sustainable therapy success with long-lasting stable subjective benefit even to our "pioneer patients" treated almost two decades ago.

Identifiants

pubmed: 31622360
doi: 10.1371/journal.pone.0223488
pii: PONE-D-19-12273
pmc: PMC6797194
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0223488

Déclaration de conflit d'intérêts

The author(s) received no specific funding for this work.

Références

Radiographics. 2004 Nov-Dec;24(6):1637-53
pubmed: 15537974
J Trauma. 2009 Dec;67(6):1327-32
pubmed: 20009686
AJNR Am J Neuroradiol. 2001 Sep;22(8 Suppl):S22-5
pubmed: 11686070
J Trauma. 2009 Feb;66(2):E28-31
pubmed: 19204498
Interv Neuroradiol. 2013 Sep;19(3):344-52
pubmed: 24070084
J Neurosurg. 2011 Jan;114(1):129-32
pubmed: 20136392
World J Radiol. 2013 Apr 28;5(4):143-55
pubmed: 23671750
J Neurosurg. 2010 Mar;112(3):589-94
pubmed: 19591548
AJNR Am J Neuroradiol. 2010 Aug;31(7):1216-21
pubmed: 20299427
Acta Neurochir (Wien). 2003 Jan;145(1):17-29
pubmed: 12545258
Neuroradiology. 2011 Dec;53(12):983-92
pubmed: 21161199
J Neurosurg. 1996 Mar;84(3):400-4
pubmed: 8609550
Int Ophthalmol Clin. 2018 Spring;58(2):271-294
pubmed: 29517654
Neuroradiol J. 2014 Sep;27(4):461-70
pubmed: 25196621
J Trauma. 2007 Nov;63(5):1014-20; discussion 1020
pubmed: 17993945
Interv Neuroradiol. 2014 Jul-Aug;20(4):461-75
pubmed: 25207910
Radiology. 1983 Oct;149(1):149-57
pubmed: 6611922
J Trauma. 1994 Sep;37(3):473-9
pubmed: 8083912
Neuroradiology. 2013 Oct;55(10):1213-20
pubmed: 23828324
Neurosurgery. 1995 Feb;36(2):239-44; discussion 244-5
pubmed: 7731502
J Neurosurg. 1974 Aug;41(2):125-45
pubmed: 4841872
J Neurosurg. 1985 Feb;62(2):248-56
pubmed: 3968564
Arch Ophthalmol. 1989 Jan;107(1):87-92
pubmed: 2910291
J Clin Neurosci. 2015 May;22(5):859-64
pubmed: 25682541

Auteurs

Lorenz Ertl (L)

Institute of Neuroradiology, University Hospital, LMU Munich, Munich, Germany.
Radiologie Augsburg-Friedberg ÜBAG, Augsburg, Germany.

Hartmut Brückmann (H)

Institute of Neuroradiology, University Hospital, LMU Munich, Munich, Germany.

Maximilian Patzig (M)

Institute of Neuroradiology, University Hospital, LMU Munich, Munich, Germany.

Gunther Fesl (G)

Institute of Neuroradiology, University Hospital, LMU Munich, Munich, Germany.
Radiologie Augsburg-Friedberg ÜBAG, Augsburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH